AU Patent

AU2015230797B2 — Drug eluting ocular implant

Assigned to Glaukos Corp · Expires 2018-06-14 · 8y expired

What this patent protects

H:\sxd\lnterwoven\NRPortbl\DCC\SXD\8460760 _docx-16/09/2015 Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of sym…

USPTO Abstract

H:\sxd\lnterwoven\NRPortbl\DCC\SXD\8460760 _docx-16/09/2015 Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015230797B2
Jurisdiction
AU
Classification
—
Expires
2018-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Glaukos Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.